PMC10438988_01
Case report timeline. 1L, first line; 2L, second line; 3L, third line.
fonc-13-1214660-g001.jpg
PMC10438988_01_fonc-13-1214660-g001.jpg
f1
BC of the right breast ( Figure 1 ).
Baseline mammography showing pathological lump in the right breast.
fonc-13-1214660-g002.jpg
PMC10438988_01_fonc-13-1214660-g002.jpg
f2
Breast and axillary lymph node ultrasound scan showed a nodule with irregular margins (23 mm diameter) in the upper-outer quadrant of the right breast. Bilateral mammography demonstrated radiopacity in the right breast and fine-needle aspiration biopsy retrieved malignant cells (C5) ( Figure 2 ).
First evidence of metastatic disease on baseline PET-CT scan.
fonc-13-1214660-g003.jpg
PMC10438988_01_fonc-13-1214660-g003.jpg
f3
PET-CT scan showed involvement of skin of the left breast, increased uptake in multiple lymph nodes of the left axilla and left internal mammary, and bone infiltrations (fourth and sixth left ribs) ( Figure 3 ). Pathological examination showed skin metastasis from breast carcinoma (ER: 0%, PgR: 0%, Ki-67: 80%, HER2-neu: 0).
PMC10438988_02
PMC10438988_03
(A) CT scan images of left chest wall disease progression at enrolment in the IMpassion131 trial. (B) CT scan images at enrolment in CLAG525B2101 trials. (C) Complete response after 6 months of treatment with olaparib; no contrast enhancement at PET-CT scan.
fonc-13-1214660-g004.jpg
PMC10438988_04_fonc-13-1214660-g004.jpg
f4
In February 2020, as a patient with a germline BRCA mutation who had received no more than two previous chemotherapy regimens for metastatic disease, she was eligible for olaparib (300 mg twice daily) therapy ( Figure 4B ). There was no evidence of increased uptake on PET/CT scan ( Figure 4C ).
PMC10438988_04
(A) CT scan images of left chest wall disease progression at enrolment in the IMpassion131 trial. (B) CT scan images at enrolment in CLAG525B2101 trials. (C) Complete response after 6 months of treatment with olaparib; no contrast enhancement at PET-CT scan.
fonc-13-1214660-g004.jpg
PMC10438988_04_fonc-13-1214660-g004.jpg
f4
In February 2020, as a patient with a germline BRCA mutation who had received no more than two previous chemotherapy regimens for metastatic disease, she was eligible for olaparib (300 mg twice daily) therapy ( Figure 4B ). There was no evidence of increased uptake on PET/CT scan ( Figure 4C ).